Incyte Corp
(WBO:INCY)
€
70.36
0 (0%)
Market Cap: 13.69 Bil
Enterprise Value: 12.09 Bil
PE Ratio: 552.00
PB Ratio: 4.70
GF Score: 92/100 
Incyte Corp at RBC Capital Markets Global Healthcare Conference Transcript
May 16, 2023 / 02:30PM GMT
Release Date Price:
€70.36
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst
RBC Capital Markets. We're really pleased to have our next presenting company Incyte here with us today. Representing Incyte, we have Christiana Stamoulis, their CFO, and Steven Stein, their Chief Medical Officer.
Christiana and Steven, thank you guys so much for being here.
Steven H. Stein
Incyte Corporation - Executive VP & Chief Medical Officer
Thank you.
Christiana Stamoulis
Incyte Corporation - Executive VP & CFO
Thank you.
Questions & Answers
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst
So there's a lot to talk about. A lot going on in the commercial and strategic and R&D front. And so we'll try to touch on as much as we can in the next 25 minutes. But maybe we can start with Opzelura, you're coming off of first quarter earnings. And where I would love to learn a little bit more about the
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers